Granules India’s arm gets EIR from USFDA for pre-approval inspection

05 Nov 2025 Evaluate

Granules India’s wholly-owned foreign subsidiary – Granules Pharmaceuticals, Inc. located in Chantilly, Virginia, USA, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) conducted by USFDA in June 2025 for a first-to-file controlled substance ANDA. There was one observation during the inspection, and it has been resolved. 

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

552.70 -21.25 (-3.70%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×